Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.51 USD
+0.02 (0.63%)
Updated Apr 26, 2024 03:36 PM ET
After-Market: $2.49 -0.02 (-0.62%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CLLS 2.51 +0.02(0.63%)
Will CLLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLLS
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
Other News for CLLS
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
Cellectis Presents Novel TALENĀ® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis Unveils Groundbreaking Gene-Editing Advances
Cellectis Unveils Gene Therapy Breakthrough
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs